Brisbane, Australia, 11 May 2020 — ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to advise that ResAppDx-EU, ResApp’s smartphone-based acute respiratory diagnostic test, has been under evaluation at a federal government-funded COVID-19 respiratory clinic in Brisbane for the past month. To assist during the COVID-19 pandemic, ResApp has now provided the clinic a license for the clinical use of ResAppDx-EU at no cost through to September 1, 2020.
Health Hub Doctors Morayfield was the first respiratory clinic established with federal government funding to take pressure off local hospitals by treating mild-moderate respiratory illnesses and assessing patients requiring COVID-19 testing. The clinic sees up to 300 patients per day and has 65 general practitioners on staff.
ResAppDx-EU is being used by doctors at the clinic to triage patients who present with respiratory symptoms, helping identify illnesses such as lower respiratory tract infections, pneumonia, asthma exacerbations and COPD exacerbations.
“Mild-moderate respiratory illnesses are the most common conditions that we see, with many patients presenting with respiratory symptoms that may or may not be COVID-19 related,” said Dr Evan Jones, Director of Health Hub Doctors Morayfield and Associate Professor of the University of the Sunshine Coast. “Our doctors have found ResAppDx-EU invaluable in helping them make differential diagnoses of respiratory disease. Being a non-contact diagnostic aid, ResAppDx-EU is especially useful when assessing patients in the difficult conditions associated with managing possible COVID-19 cases.”
Tony Keating, CEO and Managing Director of ResApp added, “Our goal is to help doctors continue to make high quality diagnoses even in the challenging conditions they currently face, where patient examinations require enhanced levels of personal protective equipment or are restricted to telehealth. We are pleased to provide Health Hub Doctors Morayfield with a no cost license to assist during the COVID-19 pandemic and generate further real-world evidence of how ResAppDx-EU enhances the diagnosis and treatment of patients presenting with respiratory symptoms.”
About ResApp Health Limited
ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp’s regulatory-approved and clinically-validated products include ResAppDx-EU, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, an at-home sleep apnoea screening app for consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit www.resapphealth.com.au.
ResApp Health Limited
ABN 51 094 468 318
Level 12, 100 Creek St, Brisbane, QLD 4000
© 2021 ResApp Health Limited. All rights reserved. US Patent No. 10,098,569, Australian Patent No. 2013239327, Japanese Patent No. 6,435,257, South Korean Patent No. 1020812410000 and Patents Pending. ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States and other countries. ResAppDx is not available for sale in the United States.